BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioMarin (BMRN) Reiterates Profitability in 2017 - Piper Jaffray
February 26, 2016 9:46 AM ESTPiper Jaffray analyst, Joshua Schimmer, sees numerous catalysts for BioMarin (NASDAQ: BMRN) as the company marches toward profitability. No change to Overweight rating but the PT is revised down to $107.
BMRN has spent years with aggressive opex and burning cash on a promising pipeline. But much of that pipeline is now close to graduating towards commercial products and it's time for the company to move towards generating cash flows for investors while also finding new programs to replace... More
BioMarin Pharma (BMRN) Misses Q4 EPS Views
February 25, 2016 4:04 PM ESTBioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.39, $0.60 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $227.9 million versus the consensus estimate of $224.38 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.05-1.10 billion, versus the consensus of... More
